Clinical Trial

LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

Study acronym: LEANOX
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Cytotoxic chemotherapy is usually scaled to the body surface area (BSA), and is currently not adjusted to the body proportions of lean and fat (i.e. body composition) of individual patients. Patients with low muscle mass behave like patients "overdosed" with chemotherapy resulted in dose-limiting toxicities (e.g. dose reductions, treatment delays or permanent treatment discontinuation), independently of the patient's weight.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2017-08-18; most recent amendment 2025-02-11.
Status change: Recruiting → Active, Not Recruiting 2022-02-11
Trial Details
NCT Number NCT03255434
Lead Sponsor Institut du Cancer de Montpellier - Val d'Aurelle
Conditions Stage III Colon Cancer
Enrollment 160 participants
Start Date 2017-11-01
Primary Completion 2022-07-28 (estimated)
Study Completion 2025-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-13